Form 4: Aptevo Therapeutics Director Exercises Stock Options
SEC Filing
Director Zsolt Harsanyi exercised stock options and converted restricted stock units into common stock of Aptevo Therapeutics on June 1st and 2nd, 2024.
Summary
- Zsolt Harsanyi, a director of Aptevo Therapeutics Inc., executed transactions involving the company's stock on June 1 and June 2, 2024.
- These transactions involved the conversion of Restricted Stock Units (RSUs) into common stock.
- On June 1, 2024, 7 RSUs were converted into 199 shares of common stock.
- On June 2, 2024, 81 RSUs were converted into 280 shares of common stock.
- The reported amounts reflect a 1-for-44 reverse stock split that Aptevo Therapeutics implemented on March 5, 2024.
Sentiment
Score: 5
Explanation: This is a routine disclosure of insider transactions, and the sentiment is neutral.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like directors, make transactions in their company's stock; these filings provide transparency to the market.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| June 1, 2021 | Reporting person was granted 893 (20 post-split) RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022. |
| June 1, 2022 | First vesting date of RSUs granted on June 1, 2021. |
| June 2, 2023 | Reporting person was granted 3,571 (81 post-split) RSUs, vesting in full on the first anniversary of the date of grant. |
| March 5, 2024 | Aptevo Therapeutics effected a 1-for-44 reverse stock split. |
| June 1, 2024 | Director converted 7 RSUs into 199 shares. |
| June 2, 2024 | Director converted 81 RSUs into 280 shares. |
| June 3, 2024 | Date of the Form 4 filing. |
Keywords
Aptevo Therapeutics, Form 4, SEC, Director, Stock Options, RSU, Zsolt Harsanyi, Reverse Stock Split
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.